ArticleEuropean journal of immunology2026
Serological Predictors of Protection from Infection Upon Household Exposure to SARS-CoV-2.
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serological Predictors of Protection from Infection Upon Household Exposure to SARS-CoV-2.European journal of immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Correlates of protection against symptomatic and severe breakthrough SARS-CoV-2 infections are well characterized. However, correlates of protection against virus transmission are poorly defined due to a lack of evidence in well-designed prospective clinical trials. We studied a Croatian cohort of individuals with documented household exposure to SARS-CoV-2 in late 2022/early 2023. Sera were acquired at the time of the COVID-19 diagnosis of the index case and before symptom onset of the test case. Samples were comprehensively analyzed for predictors of protection against virus transmission. PCR-negative participants at day 0 were recalled 14 days later and re-tested by PCR and IgM ELISA to identify any virus transmission, including asymptomatic ones. Out of nearly 200 tested serological parameters, several serological features differed between the participants that became PCR-positive during the study period and those that remained PCR-negative, although none remained significant after correction for multiple testing in the full cohort. Titers of variant-specific neutralizing antibody showed the biggest difference and were higher in the uninfected subgroup. Since recent antigenic exposure may confound results, we identified the recipients exhibiting IgM seroconversion and censored them from the study. This refinement clearly separated infected and uninfected individuals by variant-specific neutralization titers and IgA1 responses to BA4/5 RBD, which remained significant after correction. Therefore, our data indicate that high IgA1 and neutralizing titers may be predictive serum correlates of protection against SARS-CoV-2 transmission in intense contacts among household members, but only if variant-specific antigen is used in serological assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.